Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Imeglimin in Healthy Japanese Subjects
NCT02373150Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Feb 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imeglimin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Poxel SA. Primary endpoints: Peak Plasma Concentration at Day 13, Area Under the Concentration-Time Curve at Day 13 and 2 more. Started Feb 2015; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02373150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373150.